What is Applied Stemcell?
Applied Stemcell operates as a prominent Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) within the cell and gene therapy sector. The company is dedicated to advancing gene editing and stem cell therapy development, leveraging two key platforms: CRISPR/TARGATT Genome Editing and induced pluripotent stem cells (iPSC) with GMP grade capabilities. This focus positions Applied Stemcell as a crucial partner for organizations aiming to bring novel therapeutics to market, particularly in the rapidly evolving fields of precision medicine and regenerative therapies.
How much funding has Applied Stemcell raised?
Applied Stemcell has raised a total of $25M across 5 funding rounds:
Series B
$1.9M
Series C
$2.6M
Series D
$19M
Debt
$1M
Debt
$500K
Series B (2010): $1.9M, investors not publicly disclosed
Series C (2013): $2.6M, investors not publicly disclosed
Series D (2016): $19M supported by Ping An Ventures, BioSciKin, Vi-Ventures, and Hermed Capital
Debt (2020): $1M featuring PPP
Debt (2021): $500K backed by PPP
Key Investors in Applied Stemcell
Ping An Ventures
Ping An Ventures, part of the broader Ping An Insurance Group, is a significant player in financial services, specializing in insurance, banking, and investment banking. Their involvement suggests a strategic interest in the financial viability and market potential of Applied Stemcell's therapeutic development.
BioSciKin
BioSciKin (BSK) is an innovation platform focused on China's life science sector, particularly novel therapeutics, medical devices, and mobile healthcare. Their investment indicates a strategic alignment with Applied Stemcell's mission to advance precision medicine and therapeutic development.
Vi-Ventures
Vi-Ventures is an investment firm with a focus on TMT and healthcare technology, aiming to support companies entering or expanding within the Chinese market. Their participation highlights Applied Stemcell's potential for international growth and market penetration.
What's next for Applied Stemcell?
With a substantial total funding amount and a recent strategic investment, Applied Stemcell is poised for accelerated growth and expanded operational capacity. The company's commitment to developing advanced therapeutic platforms suggests a strategic focus on scaling its CDMO services and potentially broadening its research and development initiatives. Future endeavors will likely involve further integration of its CRISPR/TARGATT and iPSC platforms to support a wider range of clients and complex therapeutic projects, solidifying its role in the burgeoning cell and gene therapy landscape.
See full Applied Stemcell company page
